Farmako Healthcare vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 39)
Farmako Healthcare logo

Farmako Healthcare

EmergingHealthcare

General

Bengaluru 30-minute medicine delivery with digital health records and chronic care management; YC W20 $3.1M at ₹10.7Cr revenue with 36% CAGR competing with PharmEasy and 1mg for India pharmacy delivery.

AI VisibilityBeta
Overall Score
D39
Category Rank
#403 of 596
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
35
Gemini
38

About

Farmako Healthcare is a Bengaluru-based healthtech platform — backed by Y Combinator (W20) and HOF Capital with $3.1 million raised including a $1.6 million round in August 2024 and a pre-Series A in June 2025 — providing ultra-fast medicine delivery (30-minute delivery within service areas), digital health records management, and personalized health insights for patients managing chronic conditions and routine pharmacy needs in Indian metros. Founded in 2019 and generating ₹10.7 crore (approximately $1.3 million USD) in annual revenue as of March 2024 with 36% revenue CAGR and a 63-person team, Farmako serves the medication adherence and pharmacy access market in India's urban health ecosystem.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

39
Overall Score
93
#403
Category Rank
#1
87
AI Consensus
80
stable
Trend
stable
36
ChatGPT
94
35
Perplexity
89
38
Gemini
94
39
Claude
92
40
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.